San Diego, California, United States BioMed Ventures is the famous VC, which was founded in 2010. The main department of described VC is located in the San Diego. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the BioMed Ventures, startups are often financed by Valley Ventures, Solstice Capital, Clarus Ventures. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Sofinnova Investments, Solas BioVentures. In the next rounds fund is usually obtained by Solas BioVentures, Sofinnova Investments, Silicon Valley Bank.
Considering the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. Comparing to the other companies, this BioMed Ventures performs on 11 percentage points more the average number of lead investments. The high activity for fund was in 2015. The increased amount of exits for fund were in 2015. Deals in the range of 10 - 50 millions dollars are the general things for fund. The average startup value when the investment from BioMed Ventures is 50-100 millions dollars. The fund is generally included in less than 2 deals every year.
The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Medical Device, Health Care. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Auspex Pharmaceuticals, Genalyte, Compass Therapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Alabbar Enterprises | Dubai, United Arab Emirates |
| APAC Realty | Central, Central Region, Singapore |
| APEX Limited Partners | - |
| Beta Catalyst | Chiyoda, Japan |
| Canna Angels | - |
| Flightpath Ventures | California, San Francisco, United States |
| Frontier Communications | Connecticut, Stamford, United States |
| iVision Ventures | Beijing, Beijing, China |
| Luzerner Kantonalbank | Lucerne, Luzern, Switzerland |
| Monarch Ventures | Charlotte, North Carolina, United States |
| Runway Venture Partners | New York, New York, United States |
| Samwhan Corporation | - |
| SNBL USA | - |
| Strandview Capital | California, El Segundo, United States |
| Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi | Beijing, China, Haidian |
| Toibb Enterprises | - |
| Xssentials LLC | - |
| Yiqiao Gufen | - |
| Zhangshushi Fenghua Touzi guanli Zhongxin | China, Guangdong, Jiangxi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Fauna Bio | $9M | 21 Sep 2021 | Berkeley, California, United States | ||
Amplyx Pharmaceuticals | $53M | 19 May 2020 | San Diego, California, United States | ||
Compass Therapeutics | $49M | 12 Jul 2018 | Boston, Massachusetts, United States | ||
Amplyx Pharmaceuticals | $67M | 01 Aug 2017 | San Diego, California, United States | ||
Effector Therapeutics | $38M | 24 Jul 2017 | San Diego, California, United States | ||
NeuroVia | $14M | 20 Jul 2017 | San Francisco, California, United States | ||
Sensely | $8M | 14 Feb 2017 | San Francisco, California, United States | ||
Effector Therapeutics | $40M | 23 Dec 2015 | San Diego, California, United States | ||
Amplyx Pharmaceuticals | $40M | 11 Nov 2015 | San Diego, California, United States |
– Fauna Bio is an Emeryville, California-based biotechnology company leveraging animal genomics to improve human health.
– The company raised $9m in Seed funding.
– The round was led by LifeForce Capital with participation from True Ventures, Boom Capital, Pacific 8 Ventures, BioMed Ventures, Vibe Capital and Arcadia Science.
– The new investment will be used to expand its drug discovery platform Convergence while accelerating the discovery of new therapeutic targets for human diseases across a broad range of indications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Fauna Bio | $9M | 21 Sep 2021 | Berkeley, California, United States | ||
Amplyx Pharmaceuticals | $53M | 19 May 2020 | San Diego, California, United States | ||
Compass Therapeutics | $49M | 12 Jul 2018 | Boston, Massachusetts, United States | ||
Amplyx Pharmaceuticals | $67M | 01 Aug 2017 | San Diego, California, United States | ||
Effector Therapeutics | $38M | 24 Jul 2017 | San Diego, California, United States | ||
NeuroVia | $14M | 20 Jul 2017 | San Francisco, California, United States | ||
Sensely | $8M | 14 Feb 2017 | San Francisco, California, United States | ||
Effector Therapeutics | $40M | 23 Dec 2015 | San Diego, California, United States | ||
Amplyx Pharmaceuticals | $40M | 11 Nov 2015 | San Diego, California, United States |
